Prostate Biopsy

Steven Jones, MD, is the Vice Chairman of hte Glickman Urological Institute at the Cleveland Clinic Foundation, one of the foremost departments of urology in the world.  He is an expert in many aspects of urological science and medicine and has assembled the greatest international team to address the questions surrounding prostate biopsy.  

Defining the Problem: From Subclinical Disease to Clinically Insignificant Prostate Cancer.- What Every Patient Should Know about Prostate Cancer Before He Submits to Biopsy of His Prostate.- Prostate-Specific Antigen and Prostate Cancer Screening.- The Role of Complexed Prostate-Specific Antigen in Prostate Cancer Screening.- Newly Recognized Forms of Prostate-Specific Antigen and Emerging Molecular Markers.- The Role of Prostate-Specific Antigen Velocity in the Diagnosis and Management of Prostate Cancer.- Prostate Cancer Screening: Navigating the Controversy.- Prostate Cancer Nomograms and How They Measure Up to Neural Networks.- Preparation for Prostate Biopsy.- Principles of Prostate Ultrasound.- Minimizing Pain and Optimizing Patient Experience During Prostate Biopsy.- Prostate Biopsy Techniques.- Biopsy Strategies—How Many and Where?.- Transperineal Prostate Biopsy.- Repeat Prostate Biopsies and the Vienna Nomograms.- Saturation Biopsy for Detection and Characterization of Prostate Cancer.- Pathologic Implications of Prostate Biopsy.- Complications of Transrectal Ultrasound—Guided Prostate Biopsy.- Management and Controversies of High-Grade Prostatic Intraepithelial Neoplasia and Atypical Small Acinar Proliferation on Prostate Biopsy.- Future Directions in Prostate Cancer Diagnosis.